Limits...
Protective effect of rosuvastatin treatment by regulating oxidized low-density lipoprotein expression in a rat model of liver fibrosis

View Article: PubMed Central - PubMed

ABSTRACT

The present study aimed to evaluate the protective effect of rosuvastatin treatment on the mechanism of oxidized low-density lipoprotein (Ox-LDL) in rats with liver fibrosis. In total, 72 male Sprague-Dawley rats were divided into 3 groups: 24 in the control group (A), 24 in the obstructive jaundice models group (B) and 24 in the rosuvastatin group (C). Each group was further divided into four subgroups for assessment at different time-points. The obstructive jaundice models were established and rosuvastatin was administered by gavage. Liver fibrosis indicators, Ox-LDL, malonaldehyde (MDA) and superoxide dismutase (SOD), were measured and liver pathological changes were observed at weeks 1, 2, 3 and 4 after model induction. In groups B and C, the rat models were successfully established, and there were significant changes in the expression of Ox-LDL and the three liver fibrosis indicators when compared to group A (P<0.01). However, the expression of Ox-LDL and the three liver fibrosis indicators in group C were decreased compared with group B (P<0.05), while SOD increased (P<0.05) and MDA decreased (P<0.05). The three liver fibrosis indicators were different in comparison to group B (P<0.05). Thus, there appeared to be an association between the expression of Ox-LDL and liver fibrosis. Treatment with rosuvastatin could regulate the expression of Ox-LDL and improve liver fibrosis in rat models with obstructive jaundice.

No MeSH data available.


Related in: MedlinePlus

(A) Representative micrographs of the normal appearances of hepatocytes in group A. (B) Necrosis and the emergence of proliferation of hepatocytes in were observed group C. (C) Fibrous septamorphological abnormalities of hepatocytes in group B were evident (all magnification, ×200).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998105&req=5

f1-br-0-0-722: (A) Representative micrographs of the normal appearances of hepatocytes in group A. (B) Necrosis and the emergence of proliferation of hepatocytes in were observed group C. (C) Fibrous septamorphological abnormalities of hepatocytes in group B were evident (all magnification, ×200).

Mentions: Rats in group B exhibited a poor appetite, cloudy yellow urine and less activity compared to rats in group A. To evaluate whether liver fibrosis was successful, HA, LN and PCIII were tested in the blood samples of three groups every week. As shown in Table I, group A had lower levels of HA, LN and PCIII compared to group B at weeks 3 and 4 (P<0.01). In addition, the liver tissues were observed by a light microscope. As shown in Fig. 1, hepatocytes were morphologically normal and orderly in group A when liver tissues exhibited degeneration, edema, necrosis, proliferation and fibrous septa morphological abnormalities at week 4 in group B. These results demonstrated that the rat model was established.


Protective effect of rosuvastatin treatment by regulating oxidized low-density lipoprotein expression in a rat model of liver fibrosis
(A) Representative micrographs of the normal appearances of hepatocytes in group A. (B) Necrosis and the emergence of proliferation of hepatocytes in were observed group C. (C) Fibrous septamorphological abnormalities of hepatocytes in group B were evident (all magnification, ×200).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998105&req=5

f1-br-0-0-722: (A) Representative micrographs of the normal appearances of hepatocytes in group A. (B) Necrosis and the emergence of proliferation of hepatocytes in were observed group C. (C) Fibrous septamorphological abnormalities of hepatocytes in group B were evident (all magnification, ×200).
Mentions: Rats in group B exhibited a poor appetite, cloudy yellow urine and less activity compared to rats in group A. To evaluate whether liver fibrosis was successful, HA, LN and PCIII were tested in the blood samples of three groups every week. As shown in Table I, group A had lower levels of HA, LN and PCIII compared to group B at weeks 3 and 4 (P<0.01). In addition, the liver tissues were observed by a light microscope. As shown in Fig. 1, hepatocytes were morphologically normal and orderly in group A when liver tissues exhibited degeneration, edema, necrosis, proliferation and fibrous septa morphological abnormalities at week 4 in group B. These results demonstrated that the rat model was established.

View Article: PubMed Central - PubMed

ABSTRACT

The present study aimed to evaluate the protective effect of rosuvastatin treatment on the mechanism of oxidized low-density lipoprotein (Ox-LDL) in rats with liver fibrosis. In total, 72 male Sprague-Dawley rats were divided into 3 groups: 24 in the control group (A), 24 in the obstructive jaundice models group (B) and 24 in the rosuvastatin group (C). Each group was further divided into four subgroups for assessment at different time-points. The obstructive jaundice models were established and rosuvastatin was administered by gavage. Liver fibrosis indicators, Ox-LDL, malonaldehyde (MDA) and superoxide dismutase (SOD), were measured and liver pathological changes were observed at weeks 1, 2, 3 and 4 after model induction. In groups B and C, the rat models were successfully established, and there were significant changes in the expression of Ox-LDL and the three liver fibrosis indicators when compared to group A (P&lt;0.01). However, the expression of Ox-LDL and the three liver fibrosis indicators in group C were decreased compared with group B (P&lt;0.05), while SOD increased (P&lt;0.05) and MDA decreased (P&lt;0.05). The three liver fibrosis indicators were different in comparison to group B (P&lt;0.05). Thus, there appeared to be an association between the expression of Ox-LDL and liver fibrosis. Treatment with rosuvastatin could regulate the expression of Ox-LDL and improve liver fibrosis in rat models with obstructive jaundice.

No MeSH data available.


Related in: MedlinePlus